TheChek News Flow

>>> Up

* Allegro Raised to Overweight at Morgan Stanley; PT 39 zloty

* B&M European Raised to Buy at Shore Capital (+)

* Bakkavor Raised to Buy at Goodbody (+)

* First Solar Raised to Equal-Weight at Morgan Stanley

* Halfords Raised to Buy at Peel Hunt; PT 275 pence (+)

* Krones Raised to Buy at HSBC; PT 124 euros

* Stellantis Raised to Outperform at BNPP Exane; PT $23.60
* UCB Raised to Buy at Deutsche Bank; PT 100 euros

>>> Down

* Accentro Real Estate Cut to Hold at SRC Research; PT 1.50 euros

* Genmab Cut to Sector Perform at RBC; PT 2,900 kroner

* Hikma Cut to Sector Perform at RBC; PT 2,150 pence

* Hochtief Cut to Hold at HSBC; PT 109 euros
* Jungheinrich Cut to Hold at HSBC; PT 33 euros

* PolyPeptide Group Cut to Sell at Mirabaud Securities

* SynAct Pharma Cut to Hold at ABG; PT 17 kronor

>>> Initiation

* Adecco Rated New Hold at SocGen; PT 37 Swiss francs

* Amgen Rated New Buy at HSBC; PT $320

* Biogen Rated New Buy at HSBC; PT $360

* Bluebird Bio Rated New Buy at HSBC; PT $4.21

* Diploma Rated New Overweight at Morgan Stanley; PT 3,725 pence

* Gilead Rated New Reduce at HSBC; PT $71

* J&J Rated New Hold at HSBC; PT $175

* JDE Peet's Cut to Hold at Deutsche Bank; PT 28 euros
* Randstad Rated New Sell at SocGen; PT 45 euros

* Sartorius Rated New Hold at Jefferies; PT 345 euros

* Sartorius Stedim Biotech Rated New Buy at Jefferies

* Siemens Energy Rated New Overweight at Barclays; PT 19 euros

* Vestas Rated New Underweight at Barclays; PT 99 kroner (+)

* Zoetis Rated New Buy at HSBC; PT $230

>>> Call

* Allegro Raised at Morgan Stanley, Deliveroo Food Delivery Pick

* Bakkavor Upgraded to Buy at Goodbody After Encouraging 1H Beat (+)

* Genmab, Hikma Both Downgraded at RBC With Shares at Fair Value

* Goldman Seeing Some Opportunities in China-Exposed Global Stocks
* JPMorgan’s Kolanovic Keeps S&P Year-End Price Target at 4,200

* PolyPeptide Cut to Sell as Mirabaud; Needs to Restore Confidence (+)

* Sartorius Stedim Initiated at Buy, Sartorius a Hold at Jefferies

* WH Smith Has Scope for Future Cash Returns, FY in Line: RBC (+)